SGN-B6A for Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial is testing a new drug called sigvotatug vedotin alone and with other treatments to see if it is safe and effective for people with solid tumors. It will also check for any side effects. The study includes different parts to determine the best dose and to see how well the drug works alone and in combination with other treatments.
Do I need to stop my current medications to join the trial?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What safety data exists for SGN-B6A and related treatments?
What makes the drug SGN-B6A unique for treating cancer?
What data supports the effectiveness of the drug SGN-B6A for cancer treatment?
The research highlights the effectiveness of targeting PD-L1, a protein that helps tumors evade the immune system, using imaging agents like 68Ga-labeled compounds. This suggests that therapies targeting PD-L1, such as those involving Pembrolizumab (a component of the SGN-B6A treatment), may be effective in treating cancers by enhancing the immune system's ability to attack tumor cells.1112131415
Who Is on the Research Team?
Pfizer CT.gov Call Center
Principal Investigator
Pfizer
Are You a Good Fit for This Trial?
This trial is for adults with certain advanced solid tumors, including esophageal, breast, lung cancers and more. Participants must have relapsed or be intolerant to standard treatments. They should not have received prior therapies that caused severe immune reactions and must not have active brain metastases or serious infections.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Dose Escalation (Part A)
Determine the appropriate dose of sigvotatug vedotin for participants
Dose Expansion (Part B)
Evaluate the safety and efficacy of the determined dose of sigvotatug vedotin
Combination Therapy (Parts C and D)
Assess the safety and efficacy of sigvotatug vedotin in combination with pembrolizumab and/or chemotherapy
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Pembrolizumab
- SGN-B6A
Find a Clinic Near You
Who Is Running the Clinical Trial?
Seagen, a wholly owned subsidiary of Pfizer
Lead Sponsor
Seagen Inc.
Lead Sponsor
Dr. Roger Dansey
Seagen Inc.
Chief Medical Officer since 2018
MD from University of Witwatersrand
David R. Epstein
Seagen Inc.
Chief Executive Officer since 2022
BSc in Pharmacy from Rutgers University, MBA from Columbia University